Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro

Creative Commons License

Kankilic B., Bayramli E., Kilic E., Dagdeviren S., Korkusuz F.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, cilt.469, sa.11, ss.3222-3228, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 469 Sayı: 11
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1007/s11999-011-2082-9
  • Dergi Adı: CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.3222-3228
  • Orta Doğu Teknik Üniversitesi Adresli: Evet

Özet

Osteomyelitis caused by Methicillin-resistant Staphylococcus aureus (MRSA) often requires surgery and prolonged systemic antibiotic treatment. Local antibiotic delivery systems of bioceramics or polymers have been developed to treat osteomyelitis. A disadvantage of biodegradable polymers is the initial burst of antibiotics into the environment; one advantage of bioceramics is its osteoconductivity. We therefore developed a vancomycin-containing poly-l-lactic acid/beta-tricalcium phosphate (PLLA/beta-TCP) composite to control antibiotic release and stimulate bone formation.